[HTML][HTML] Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer
Although precision medicine has had a mixed impact on the clinical management of patients
with advanced-stage cancer overall, for NSCLC, and more specifically for lung …
with advanced-stage cancer overall, for NSCLC, and more specifically for lung …
Precision medicine in non-small cell lung cancer: Current applications and future directions
Advances in biomarkers, targeted therapies, and immuno-oncology have transformed the
clinical management of patients with advanced NSCLC. For oncogene-driven tumors, there …
clinical management of patients with advanced NSCLC. For oncogene-driven tumors, there …
Persistent mutation burden drives sustained anti-tumor immune responses
Tumor mutation burden is an imperfect proxy of tumor foreignness and has therefore failed
to consistently demonstrate clinical utility in predicting responses in the context of …
to consistently demonstrate clinical utility in predicting responses in the context of …
Meta-analysis of tumor-and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
Checkpoint inhibitors (CPIs) augment adaptive immunity. Systematic pan-tumor analyses
may reveal the relative importance of tumor-cell-intrinsic and microenvironmental features …
may reveal the relative importance of tumor-cell-intrinsic and microenvironmental features …
Network-based machine learning approach to predict immunotherapy response in cancer patients
Immune checkpoint inhibitors (ICIs) have substantially improved the survival of cancer
patients over the past several years. However, only a minority of patients respond to ICI …
patients over the past several years. However, only a minority of patients respond to ICI …
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C …
S Peters, R Dziadziuszko, A Morabito, E Felip… - Nature medicine, 2022 - nature.com
Tumor mutational burden (TMB) is being explored as a predictive biomarker for cancer
immunotherapy outcomes in non-small cell lung cancer. BFAST (NCT03178552)—an open …
immunotherapy outcomes in non-small cell lung cancer. BFAST (NCT03178552)—an open …
Somatic HLA class I loss is a widespread mechanism of immune evasion which refines the use of tumor mutational burden as a biomarker of checkpoint inhibitor …
M Montesion, K Murugesan, DX Jin, R Sharaf… - Cancer Discovery, 2021 - AACR
Neoantigen presentation arises as a result of tumor-specific mutations and is a critical
component of immune surveillance that can be abrogated by somatic LOH of the human …
component of immune surveillance that can be abrogated by somatic LOH of the human …
A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer
Murine tissues harbor signature γδ T cell compartments with profound yet differential
impacts on carcinogenesis. Conversely, human tissue-resident γδ cells are less well …
impacts on carcinogenesis. Conversely, human tissue-resident γδ cells are less well …
[HTML][HTML] Deregulation of HLA-I in cancer and its central importance for immunotherapy
It is now well accepted that many tumors undergo a process of clonal selection which means
that tumor antigens arising at various stages of tumor progression are likely to be …
that tumor antigens arising at various stages of tumor progression are likely to be …
Tumour mutational burden: clinical utility, challenges and emerging improvements
Tumour mutational burden (TMB), defined as the total number of somatic non-synonymous
mutations present within the cancer genome, varies across and within cancer types. A first …
mutations present within the cancer genome, varies across and within cancer types. A first …